Compare Dow Inc (DOW) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Repligen Corporation Common Stock — how do they compare? Dow Inc trades at $29.46 (market cap $21.09B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays a 4.8% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 83 Days and Repligen Corporation Common Stock for 0 Days on average.
| DOW | RGEN | |
|---|---|---|
Market Cap | $21.09B | $11.31B |
Volume | 8,218,399 | 1,216,919 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $194.57 |
52-Week Low | $20.95 | $102.87 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $36.78B | $11.20B |
Dividend Yield | 4.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.51, up 1.39% with bearish technical signals despite recent earnings beats. The company faces fundamental challenges with negative net income margin (-3.13%) and ROE (-7.86%), though valuation metrics show moderate P/S (0.5) and P/B (1.3). Cash flow trends show improvement with 2025 net cash flow turning positive at $1.69B after three years of declines. Recent news highlights dividend sustainability concerns in the chemical sector.
Outlook remains cautious with analyst consensus at Hold (55.55%) and $33.80 price target offering 18.6% upside. Key risks include continued margin pressure, declining revenue trends, and high debt levels (debt-to-asset ratio 29.87%). The stock presents value opportunity for patient investors but requires monitoring of operational turnaround and dividend sustainability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
